Abstract: A molecular detection apparatus according to an embodiment includes: a collection unit collecting a detection target gas containing a molecule to be detected; a substitution unit substituting a part of a molecular structure of at least a part of the molecule to generate a substitution product; a detector including a plurality of detection cells each having a sensor unit and an organic probe disposed at the sensor unit, the organic probe capturing the molecule or the substitution product; and a discriminator discriminating the molecule by a signal pattern based on an intensity difference of detection signals generated with the molecule or the substitution product being captured by the organic probes of the plurality of detection cells.

Abstract: A wearable device for measuring physiological parameters includes a light source having a plurality of semiconductor light emitting diodes (LEDs) each configured to generate an output optical beam, wherein at least a portion of the one or more optical beam wavelengths is a near-infrared wavelength. The light source is configured to increase signal-to-noise ratio by increasing light intensity for at least one of the LEDs and by increasing a pulse rate of at least one of the LEDs. A lens is configured to receive the output optical beam and to deliver a lens output beam to tissue. A detection system generates an output signal in response to the lens output beam reflected from the tissue, wherein the detection system is configured to be synchronized to the light source, and is located a different distance from a first one of the LEDs than a second one of the LEDs.

Abstract: There may be provided a system comprising a spectroscopic device; wherein the spectroscopic device is configured to analyze a fluid of a pool.

Abstract: The invention relates to a method for optimizing a mixture of components for the production of a target product by means of spectral analysis, preferably by means of spectral analysis (topological) in the near infrared region (NIR). The aim of the method is to produce a target product by batch mixing and/or continuous mixing of the “n” components thereof, on the basis of different flows of said components with controlled concentrations and/or flow rates, said target product requiring a set of ranges of values of physiocohemical characteristics for the commercialization thereof. According to the method, a batch mixer or a continuous mixer is supplied with said components with controlled concentrations and/or flow rates.

Abstract: A measuring rod (1) with a longitudinal axis (A) for insertion in the flow cross section of a tube and for the verification of a flowing medium in this tube having at least one first sender unit (2) for the transmission of a first acoustic or electromagnetic measuring signal (3) and at least one first receiver unit (4) for receiving the first measuring signal, wherein the first sender unit (2) and the first receiver unit (4) define a measuring section, wherein the first sender unit (2) is arranged in such a manner that the first measuring signal (3) crosses the measuring section and wherein the first receiver unit (4) is arranged in such a manner that it, at least during operation without flow, receives the first measuring signal (3) after crossing the measuring section.

Abstract: There is described an oil contamination detection system and method. The system comprises a forward sensor package, a rearward sensor package, a catalytic chamber, and a computing device. The method comprises obtaining sensor measurements from the forward sensor package and the rearward sensor package, and detecting the presence of oil in the air flow from the sensor measurements.

Abstract: An apparatus for assessment of a fluid system includes a debris monitor to receive a first flow of a fluid, the debris monitor to determine wear debris information in the first flow of the fluid; and a fluid condition monitor to receive a second flow of the fluid, the fluid condition monitor being configured to determine fluid condition information in the second flow of the fluid.

Abstract: Systems, methods, and devices for analyzing small volumes of fluidic samples, as a non-limiting example, less than twenty microliters are provided. The devices are configured to make a first sample reading, for example, measure an energy property of the fluid sample, for example, osmolality, make a second sample reading, for example, detecting the presence or concentration of one or more analytes in the fluid sample, or make both the first sample reading and the second sample reading, for example, measuring the energy property of the fluid sample as well as detecting the presence or concentration of one or more analytes in the fluid sample.

Abstract: A system and method that images biological samples and uses chromophores to analyze the imaged samples. The chromophore analysis can be done by itself or in conjunction with fluorophore analysis in High Content Imaging systems. To perform chromophore analysis the biological samples can be labeled with different chromophores and imaged using transmitted light that is at least partially absorbed by the chromophores. To also perform fluorophore analysis the samples can also be labeled with fluorophores that are excited by excitation light. The chromophore analysis and fluorophore analysis can be performed separately or concurrently using a High Content Imaging system. The system provides the expanded capability by illuminating the chromophore-labeled samples with transmitted light of different wavelengths and automatically detecting the images which represent the differential absorption of the colored lights by the sample.

Abstract: This disclosed method improves the accuracy of testing blood for the levels of contaminant, such as lead, cadmium and mercury, in individuals. The method comprises cleaning the area where the skin will be penetrated to obtain the blood sample to remove the contaminant to be measured in the blood. The cleansing is accomplished with a cleanser formulated to remove the contaminant to be measured in the blood from the surface of the skin, the pores, sweat ducts, hair follicles and sebaceous gland ducts. The method reduces contamination of the blood sample by contaminants on, and/or in the portion of the skin through which the blood sample is drawn. A premoistened wipe can also be used that mobilizes heavy metals from the skin surface, the skin pores, sweat ducts, hair follicles and sebaceous gland ducts, and is formed with a wipe substrate material selected for its affinity to bind the toxic materials.

Abstract: A blood coagulation analyzer comprises: a light irradiation unit configured to apply light onto a container configured to store a measurement specimen containing a sample and a reagent, and comprising: light sources including a first light source configured to generate light of a first wavelength for blood coagulation time measurement, a second light source configured to generate light of a second wavelength for synthetic substrate measurement, and a third light source configured to generate light of a third wavelength for immunonephelometry measurement; and optical fiber parts facing the respective light sources; a light reception part configured to receive light transmitted through the container; and an analysis unit configured to analyze the sample using an electric signal outputted from the light reception part.

Abstract: Among others, the present invention provides micro-devices for detecting or treating a disease, each comprising a first micro sensor for detecting a property of the biological sample at the microscopic level, and an interior wall defining a channel, wherein the micro sensor is located in the interior wall of the micro-device and detects the property of the biological sample in the microscopic level, and the biological sample is transported within the channel

Abstract: A novel marker for determining sensitivity to an anti-cancer agent is provided. Disclosed is a marker for determining sensitivity to an anti-cancer agent including one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A.

Abstract: Provided herein are Amyotrophic lateral sclerosis (ALS) biomarkers and methods of using these ALS biomarkers to diagnose and treat ALS.

Abstract: Methods for identifying drug-saccharide conjugates that bind the mannose receptor, C type 1, (MRC1) and may be taken up by cells expressing MRC1, and the use of such drug-saccharide conjugates for treatment of particular diseases are described. In particular, the methods for identifying insulin-saccharide conjugates that bind the MRC1 receptor and may be taken up by cells expressing the MRC1 and use of such conjugates for treatment of diabetes are described.

Abstract: Diagnostic tests and methods to assess the characteristics of a patient's native stem cell populations. A reference cell source may be selected for testing, to determine the relative health and potency of the cell population derived from that cell source based on standardized testing protocols, and to use the results to evaluate the systemic stem cell health status of the patient across the many different cell populations residing in different tissues in the body.

Abstract: The present invention concerns the development of a model to evaluate active substances targeting the epidermis. It more particularly relates to the preparation of mixed spheroids of melanocytes and keratinocytes reproducing cell interactions occurring in the epidermis, to the spheroids as such and to the uses thereof.

Abstract: A microfluidic device, method and kit for assaying and/or culturing cells are provided.

Abstract: This disclosure provides a method for determining male fertility status. The method comprises determining GM1 distribution patterns following induced sperm capacitation, identifying the frequency of distribution of various patterns, and determining if the frequency distribution of certain GM1 patterns in response to induced capacitation is altered. Based on the change in the frequency distribution patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified.

Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.

Abstract: Disclosed herein are a method and a kit using a novel marker associated with depression. The marker for depression includes one or more selected from a noradrenaline transporter and a dopamine transporter. The method for determining depression includes a step of examining an expression level of the marker for depression in a blood sample collected from a subject.

Abstract: Proteinaceous specific binding members that specifically bind to a polymeric dye are provided. Also provided are methods of using the specific binding members, e.g., in separating a polymeric dye-labeled cell from a sample, in analyte detection, etc., as described herein. Kits and systems for practicing the subject methods are also provided.

Abstract: A method and system for identifying one or more analytes in a fluid includes preparing a porous medium having one or more pores and one or more encoded regions. The one or more encoded regions can contact internal pore surface or surfaces, external surface or surfaces, or any combination thereof, of the porous medium. The one or more encoded regions can include a capture probe or binding element which selectively captures the one or more of the analytes in the fluid. One or more of the one or more encoded regions can include at least one of physical properties and chemical properties which are different from the other one or more encoded regions.

Abstract: The present invention relates to methods of measuring interaction between a first and a second molecule, for example a protein and an antibody, by conjugation of one of these molecules with nanoparticles, and measuring the interaction between the first and second molecule via changes in the optical properties of the nanoparticles. The present invention further relates to methods of coating nanoparticles.

Abstract: Provided is a manufacturing method of a sensor including the following steps. A mold having a cavity is provided. At least one chip is disposed in the cavity. The chip has an active surface and a back surface opposite to each other. The active surface faces toward a bottom surface of the cavity. A polymer material is filled in the cavity to cover the back surface of the chip. A heat treatment is performed, such that the polymer material is solidified to form a polymer substrate. A mold release treatment is performed to isolate the polymer substrate from the cavity. A plurality of conductive lines are formed on a first surface of the polymer substrate. The conductive lines are electrically connected with the chip.

Abstract: A sensing sensor includes a wiring board, a piezoelectric resonator, and a gel-like protective agent. The piezoelectric resonator has one surface side on which an adsorbing film is formed. The adsorbing film is constituted of biomolecules. The protective agent is disposed so as to cover a surface of the adsorbing film. The protective agent is configured to suppress an inactivation of the biomolecules. The channel forming member is disposed so as to cover a region of the one surface side of the wiring board including the piezoelectric resonator. The channel forming member includes an injection port of the sample solution. The flow passage is disposed between the wiring board and the channel forming member. The flow passage is configured to allow the sample solution supplied to the injection port to flow from one end side to another end side on the one surface side of the piezoelectric resonator.

Abstract: A system and method for analyzing a biomarker in a biological sample is provided. A biological sample is loaded onto a microchip and an enzyme-linked immunosorbent assay specific to the biomarker is performed on the microchip. A color image of the microchip is generated using a mobile device and a color intensity of a selected portion of the color image is determined. The color intensity is correlated with a biomarker concentration using a baseline curve calculation and the concentration of the biomarker is then reported.

Abstract: A device for determining the presence of an analyte in a sample uses a substrate shaped to define a plurality of lateral-flow channels and a detection region. Each lateral-flow channel is associated with a load spot. The substrate includes, for each of the lateral-flow channels, a fluid conducting medium, and, for the detection region, a fluid retaining medium. A first load spot receives a sample from the subject. Each of the other load spots uses a dried mixture of silk fibroin with a reagent. The detection region includes a detection reagent including a first immunoreactant. A second load spot includes a secondary detection immunoreactant. A third load spot includes a color reagent. The device implements an ELISA reaction when activated by sequentially placed aliquots of an aqueous solution.

Abstract: The invention is directed to a detection reagent for CAR expressing cells according to general formula (1) Xn—Sm—Do wherein X is a polypeptide comprising at least 20 amino acids of which at least two amino acids are connected by at least one disulfide group S is a spacer comprising at least 15 carbon atoms D is a detection moiety m, o are integers independently between 1 and 200 n is an integer between 4 and 200 with the provisio that X binds to the antigen binding domain of a chimeric antigen receptor of a cell. The detection agent can be used in a method to detect cells having an antigen binding domain of a chimeric antigen receptor (CAR) binding the detection reagent and preferable to remove the detection moiety D from the detected cell.

Abstract: A method of determining the presence or absence in a sample of a biomarker, the method comprising the steps of (a) providing a porous substrate which carries an antigen; (b) contacting the substrate with the sample; (c) contacting the substrate with a composition comprising a secondary antibody; and (d) observing the substrate. The method may enable a very quick, simple test to be carried out to determine whether or not a particular sample contains a biomarker, for example an antibody indicative of infection with a mycobacterial disease. A kit and a device for determining the presence or absence in a sample of a biomarker are also described.

Abstract: Methods for obtaining a tuberculosis assessment in a subject are provided. Aspects of the methods include identifying a subpopulation of a cellular sample of the subject having an expression level for a tuberculosis host biomarker below a threshold expression level to produce a biomarker signature; and obtaining a tuberculosis assessment for the subject from the biomarker signature. Aspects of the invention further include reagents, devices, systems, and kits thereof that find use in practicing the subject methods are provided. The methods and compositions find use in a variety of applications, including diagnosis and monitoring of TB.

Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.

Abstract: The invention concerns variants of JL7 antigens that are suitable for detecting antibodies against Trypanosoma cruzi (causing Chagas disease) in an isolated biological sample. These antigens comprise a JL7 specific amino acid sequence, said JL7 specific sequence consisting of two copies of SEQ ID NO. 2, wherein each of said two copies has an amino acid identity of at least 90% to SEQ ID NO.2 and wherein no further Trypanosoma cruzi specific amino acid sequences are present in said polypeptide. The invention also concerns a composition of polypeptides useful for the detection of antibodies against Trypanosoma cruzi that comprises the above characterized JL7 antigen along with at least one of T. cruzi polypeptides 1F8, Cruzipain, KMP-11 and PAR-2. Moreover, it relates to a method for producing JL7 antigen as well as to diagnostic methods for detecting T. cruzi antibodies using the JL7 polypeptide.

Abstract: Methods of isolating and assaying fetal extravillous trophoblast cells, including assays of RNA of the fetal extravillous trophoblast cells according to aspects of the disclosure include obtaining a maternal endocervical sample containing fetal extravillous trophoblast cells from a pregnant subject; fixing the maternal endocervical sample in an aldehyde fixative, removing fetal extravillous trophoblast cells from the maternal endocervical sample thereby producing isolated extravillous trophoblast cells, isolating and assaying RNA from the fetal extravillous trophoblast cells.

Abstract: This disclosure is directed to methods for retrieving and using at least one lymphocyte. Additionally, cell receptor sequences identified with this strategy could be used for antibody development, TCR discovery, or appropriate therapeutics development or evaluation.

Abstract: A protein composition including TorsinA or TorsinA mutant, LULL1, and a nanobody obtained by immunization using TorsinA and LULL1 is used to grow complex crystals, and three dimensional structures are determined using x-ray data of the crystals. A creening platform is built based on the determined three dimensional structures for designing a drug lead to cure dystonia.

Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.

Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.

Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.

Abstract: The invention provides a method for analyzing a protamine sample for the presence or amount of at least one nucleotidic impurity. The invention also provides a method for the quantitation of peptides in a sample of protamine comprising four major peptides and at least one related impurity.

Abstract: An apparatus for glycan analysis is disclosed. The apparatus includes a plurality of loading wells adapted to receive a plurality of samples; a plurality of capillaries arranged in correspondence with the loading wells, each of the capillaries including a first portion including a stacking gel and a second portion including a resolving gel; and a plurality of eluting wells arranged in correspondence with the capillaries and adapted to receive a portion of the samples having traversed the capillaries.

Abstract: The invention generally relates to methods for analyzing a metabolite level in a sample. In certain embodiments, methods of the invention may involve obtaining a sample, analyzing the sample using a mass spectrometry technique to determine a level of at least one metabolite in the sample, and correlating the metabolite level with an originating source of the sample, thereby analyzing the sample.

Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Epidermal Growth Factor Receptor (EGFR) protein that are particularly advantageous for quantifying the EGFR protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.

Abstract: This invention is in the field of Biomarkers. In particular, it relates to biomarker being predictive of muscle atrophy. The invention relates to the use of such biomarker for selectively treating a patient having muscle atrophy and a method of predicting the likelihood that a patient having muscle atrophy will respond to treatment with a muscle anabolic agent.

Abstract: The presently disclosed subject matter relates to a method for predicting increased risk of obesity on a non-obese subject. More particularly, the presently disclosed subject matter relates to a method of predicting increased risk of obesity in a non-obese subject by determining a level of neurotensin expression in a biological sample from the subject and comparing the level of neurotensin expression in the sample with a control level. The presently disclosed subject matter further relates to a method of preventing and/or treating obesity in a subject in need thereof by administering to the subject an effective amount of an agent that inhibits neurotensin.

Abstract: A method for determining the risk of acute kidney injury (AKI) in a mammal following cardiac surgery is provided. The method comprises determining the sample value of IL-6 or hFABP concentration, or the ratio of IL-6 to IL-10, in a biological sample from the mammal, either prior to cardiac surgery or within 6 hours following surgery; comparing the sample value to a corresponding reference value; and determining that the mammal is at risk of acute kidney injury following cardiac surgery if the sample value is greater than the corresponding reference value.

Abstract: Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.

Abstract: The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect Chitinase-3-like protein 1 as a predictive biomarker in renal injuries.